Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Inclusion Criteria: * • Symptoms of OAB for at least six months prior to randomization * ≥ 8 micturitions on average/24 hours * ≥ 1 urgency episodes on average/24 hours * with or without UUIE * Patients dissatisfied with prior oxybutynin ER or tolterodine ER treatment. Patients must have been on either treatment for at least 1 week and up to 12 months preceding this study. It is required that either oxybutynin ER or tolterodine ER was the most recent OAB medication taken. * Patients without prior darifenacin treatment Exclusion Criteria: * • A mean daily urinary volume \>3000 mL or a mean volume voided/micturition of \>300 mL as verified in the micturition diary for two consecutive days prior to Baseline * Males with post-void residual (PVR) urinary volume \>200 mL at Baseline * Clinically predominant and bothersome stress urinary incontinence, as determined by the investigator * Urinary retention or clinically significant bladder outlet obstruction as determined by the investigator Other protocol-defined inclusion / exclusion criteria may apply